BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33661186)

  • 21. ZAP70 activation is an early event of T cell immunity that involved in the anti-bacterial adaptive immune response of Nile tilapia.
    Li J; Liang W; Li K; Jiao X; Ai K; Zhang Y; Wei X; Yang J
    Dev Comp Immunol; 2021 Nov; 124():104177. PubMed ID: 34153283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70.
    Graef IA; Holsinger LJ; Diver S; Schreiber SL; Crabtree GR
    EMBO J; 1997 Sep; 16(18):5618-28. PubMed ID: 9312021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. K33-linked polyubiquitination of Zap70 by Nrdp1 controls CD8(+) T cell activation.
    Yang M; Chen T; Li X; Yu Z; Tang S; Wang C; Gu Y; Liu Y; Xu S; Li W; Zhang X; Wang J; Cao X
    Nat Immunol; 2015 Dec; 16(12):1253-62. PubMed ID: 26390156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Degradation of the Oncogenic Phosphatase SHP2.
    Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
    Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
    Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
    J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
    Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
    Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
    Kerr DL; Haderk F; Bivona TG
    Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
    Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
    Yokosuka T; Takamatsu M; Kobayashi-Imanishi W; Hashimoto-Tane A; Azuma M; Saito T
    J Exp Med; 2012 Jun; 209(6):1201-17. PubMed ID: 22641383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling.
    Tsai WC; Chen CL; Chen HC
    Oncotarget; 2015 Sep; 6(27):23845-56. PubMed ID: 26204488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of demethylincisterol A
    Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
    Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
    Liu W; Yu B; Xu G; Xu WR; Loh ML; Tang LD; Qu CK
    J Med Chem; 2013 Sep; 56(18):7212-21. PubMed ID: 23957426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
    Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
    J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Destabilizing the autoinhibitory conformation of Zap70 induces up-regulation of inhibitory receptors and T cell unresponsiveness.
    Hsu LY; Cheng DA; Chen Y; Liang HE; Weiss A
    J Exp Med; 2017 Mar; 214(3):833-849. PubMed ID: 28159798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
    Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
    J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A disease-associated mutation that weakens ZAP70 autoinhibition enhances responses to weak and self-ligands.
    Shen L; Matloubian M; Kadlecek TA; Weiss A
    Sci Signal; 2021 Feb; 14(668):. PubMed ID: 33531381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1.
    Brockdorff J; Williams S; Couture C; Mustelin T
    Eur J Immunol; 1999 Aug; 29(8):2539-50. PubMed ID: 10458769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
    Xu J; Zeng LF; Shen W; Turchi JJ; Zhang ZY
    Biochem Biophys Res Commun; 2013 Oct; 439(4):586-90. PubMed ID: 24041688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
    Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
    Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.